新型一体式腔内移植物全经皮修复复杂主动脉弓夹层的初步经验
本研究评估了新型一体式腔内移植物系统全经皮腔内修复残余弓部夹层的可行性。中位随访1年无死亡、卒中、截瘫等并发症,1例患者因分支反流导致内漏接受再次介入治疗。
要点
- 新型一体式腔内移植物系统全经皮修复残余弓部夹层技术可行
- 4例患者技术成功,30天内无主要不良事件
- 中位随访1年无死亡、卒中、截瘫等,1例内漏再干预
核心结论
- 新型一体式腔内移植物系统全经皮腔内修复残余弓部夹层在初步研究中显示技术可行。
研究设计与样本
- 回顾性纳入2023年9月至2024年1月接受一体式腔内移植物系统行主动脉弓腔内修复的残余弓部夹层患者,主要结局为术后30天内主要不良事件发生率。
主要发现
- 中位手术时间128分钟(IQR 117-167.5分钟),腔内操作时间75分钟(IQR 55.5-80.5分钟)。
- 中位随访1年(IQR 366-456天),无死亡、卒中、截瘫、移植物狭窄、断裂、移位或入路并发症。
- 1例患者因分支反流诊断为内漏,术后1个月接受腔内再干预。
临床怎么用
- 对于残余弓部夹层,可考虑采用新型一体式腔内移植物系统行全经皮腔内修复,避免颈部或锁骨上切口。
- 术后需监测内漏等并发症,必要时行再次腔内干预。
局限性
- 样本量小(仅4例),随访时间有限,长期疗效和安全性需进一步研究确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Endovascular repair has emerged as a less invasive alternative treatment for residual arch disease after limited repair of type A aortic dissection. However, cervical or supraclavicular incisions are generally required to establish access for branch bridging stent-graft deployment. This study aimed to assess the feasibility of total percutaneous endovascular arch repair using an innovative off-the-shelf unibody endograft system. METHODS: Patients who underwent endovascular aortic arch repair with a unibody endograft system for residual arch dissection from September 2023 to January 2024 were included. The primary outcome was the incidence of major adverse events within 30 days postoperatively. RESULTS: A total of 4 men with a median age of 56.5 years (interquartile range [IQR], 48-60.5 years) were included. Procedural technical success was achieved in all patients. The median surgery duration was 128 minutes (IQR, 117-167.5 minutes), with an endovascular procedure time (from the first aortic stent-graft delivery system insertion to the last bridging stent-graft delivery system retrieval) of 75 minutes (IQR, 55.5-80.5 minutes). After a median follow-up of 1 year (IQR, 366-456 days), no deaths, stroke, paraplegia, stent-graft stenosis, fractures, migrations, or access complications were observed. One patient received a diagnosis of endoleak from branch reentries and underwent endovascular reintervention 1 month postoperatively. CONCLUSIONS: Preliminary results of this study have demonstrated the technical feasibility of endovascular repair using the novel unibody endograft system for residual arch dissection through a total percutaneous approach. Further research is warranted to confirm its long-term efficacy and safety.
引用
- Hu J, Liu Y, Yang P, et al. Preliminary Experiences With a Novel Unibody Endograft System for Total Percutaneous Endovascular Repair for Complex Aortic Arch Dissection. Ann Thorac Surg. 2025. PMID: 40789500. doi:10.1016/j.athoracsur.2025.07.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。